Bond.az White LogoBond.az Black Logo

Keefe Bruyette Reiterates Bitdeer Rating on AI Shift

Keefe, Bruyette & Woods reiterates Market Perform rating on Bitdeer stock with $11.50 target amid AI mix shift and Tydal project focus.

Henry Walker
ByHenry Walker- Senior Editor
|
0

Bond.az - Keefe, Bruyette & Woods (KBW) has reiterated a Market Perform rating and $11.50 price target on Bitdeer Technologies Group (NASDAQ:BTDR) stock following Q1 2026 results released on May 14.

The firm updated its financial model with 2026 EBITDA estimates largely unchanged due to a more favorable AI cloud business mix, while lowering 2027 projections. Sealminer inventory is accumulating faster than external demand, creating potential writedown risk.

KBW highlighted that anticipated negative levered free cash flow poses elevated dilution risk for shareholders. They also pointed to increasing reliance on related-party financing as a concern.

Potential project financing for the Tydal project above capex requirements could address near-term funding needs but would reduce overall lease equity value creation. The $11.50 price target is supported by assumed favorable Tydal lease economics.

KBW stated that while a Tydal deal could improve expectations for Rockdale and Clarington leases and support share price gains, they seek better visibility on execution before assigning prospective lease value. They plan to visit the Rockdale site this week.

In other news, Bitdeer reported Q1 2026 revenue of $188.9 million, missing estimates, with EPS of -$0.68. Rosenblatt raised its price target to $25, Needham to $19, Cantor Fitzgerald to $15 with Neutral rating, and Benchmark reiterated Buy with $27 target.

This article was generated with AI support and reviewed by an editor.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...